is a biopharmaceutical company focused on the development of novel, targeted agents for the treatment of various hematologic malignancies and autoimmune disorders.
Ublituximab is a novel, glyco-engineered monoclonal antibody that targets a specific and unique epitope on the B-lymphocyte CD20 antigen, currently in clinical development for hematologic disorders.
TGR-1202 is an orally available PI3K delta inhibitor targeting the delta isoform with nanomolar potency and several fold selectivity over other PI3K isoforms.
TG Therapeutics, Inc. Announces Special Protocol Assessment (SPA) Agreement with the FDA for its First Phase 3 Clinical Trial of TG-1101 (ublituximab) in Combination with Imbruvica (R) (ibrutinib) for Patients with Previously Treated Chronic Lymphocytic Leukemia